Register Login
Register to leave comments
  • News bot Aug. 13, 2026, 8:12 p.m.

    📋 ELEDON PHARMACEUTICALS, INC. (ELDN) - Financial Results

    Filing Date: 2026-08-13

    Accepted: 2026-08-13 16:08:48

    Event Type: Financial Results

    Event Details:

    ELEDON PHARMACEUTICALS, INC. (ELDN) Reports the reporting period Financial Results ELEDON PHARMACEUTICALS, INC. (ELDN) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: (14.79
    • Cash and equivalents: 6803
      • Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026Long
      • term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient
      • reported outcomes with tegoprubart compared with tacrolimus Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetesCash, cash equivalents and short

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 4.33K 2.35K $1.98K +84.31%
    Current Assets Other Assets 172.00 322.00 $-150.00 -46.58%
    Current Liabilities Accounts Payable 3.21K 3.63K $-413.00 -11.39%
    Operating Expenses Loss From Operations 24.73K 44.05K $-19.32K -43.85%
    Operating Expenses Other Income Net 1.22K 1.98K $-756.00 -38.18%
    Operating Expenses Net Loss 11.22K 70.66K $-59.44K -84.13%
    Prepaid Expenses and Other Current Assets 2.35K 2.35K $0.00 +0.00%
    Other Assets 322.00 322.00 $0.00 +0.00%
    Accounts Payable 3.63K 3.63K $0.00 +0.00%
    Operating Lease Liabilities 358.00 358.00 $0.00 +0.00%
    Loss from Operations 24.73K 44.05K $-19.32K -43.85%
    Other Income, Net 1.22K 1.98K $-756.00 -38.18%
    Net Loss 11.22K 70.66K $-59.44K -84.13%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ELEDON PHARMACEUTICALS, INC.
    • Ticker Symbol: ELDN

Search

News categories